Last updated: February 14, 2026
Overview and Therapeutic Category
NDC 00487-9601 corresponds to Invega Sustenna (paliperidone palmitate), a long-acting injectable antipsychotic. It is used primarily for schizophrenia management. As a formulation of paliperidone, it falls under atypical antipsychotics with a focus on improving compliance in chronic mental health conditions.
Market Landscape
- Market Size: The global antipsychotic drugs market was valued at approximately USD 4.8 billion in 2022. The long-acting injectables (LAIs) segment accounts for about 25-30% of this market, reflecting growth driven by adherence benefits.
- Key Competitors: Risperdal Consta (risperidone), Abilify Maintena (aripiprazole), and decanoate formulations from Teva and Otsuka.
- Patient Population: Approximately 1.5 million individuals in the U.S. have schizophrenia, with roughly 60-70% on antipsychotic therapy. LAIs are prescribed to about 20-25% of this group, favoring adherence and relapse prevention.
Pricing Trends and Cost Dynamics
- Current Average Wholesale Price (AWP): For Invega Sustenna, list prices hover around USD 2,000 per 28-day dose, equating roughly to USD 24,000 annually per patient.
- Reimbursement and Payer Dynamics: Medicare, Medicaid, and commercial insurers cover a significant share. Reimbursement rates may vary, with pharmacies often receiving discounts, reducing net costs.
- Market Penetration: Estimated at 35-45% of eligible schizophrenia patients, driven by clinician preference, formulary policies, and patient adherence.
Historical Price Trends
- Price escalations of 2-3% annually over the past five years reflect general inflation in injectable antipsychotics.
- Introduction of biosimilars or generics is limited due to patent protections.
- Patent expiry related to formulations or delivery mechanisms could influence future prices in select markets, but Invega Sustenna remains under patent protection until at least 2027.
Price Projections (Next 5 Years)
| Year |
Projected List Price (USD/month) |
Notes |
| 2023 |
2,000 |
Current market rates |
| 2024 |
2,040 |
2% increase due to inflation |
| 2025 |
2,080 |
Continued price stability |
| 2026 |
2,130 |
Potential marginal increase |
| 2027 |
2,180 |
Possible price stabilization post-patent expiry |
Note: The projections assume no biosimilar entry or significant patent challenges. Actual pricing could be influenced by policy changes, market competition, or negotiated discounts.
Supply Chain Considerations
- Manufacturing: Otsuka Pharmaceutical owns exclusive rights and control over production, limiting generic competition.
- Distribution Dynamics: Distribution channels remain concentrated among major distributors and specialty pharmacies, maintaining pricing stability.
- Healthcare Policy Impact: Increased focus on reducing healthcare costs could influence negotiated prices, especially in public payer systems.
Potential Future Factors Influencing Price
- Biosimilar Development: No biosimilar exists as of yet, but regulatory pathways could emerge by 2028-2030.
- Patent Litigation: Ongoing patent challenges could lead to generic options, pressuring prices downward.
- Regulatory and Policy Changes: Legislation aimed at price transparency and negotiation could affect reimbursed prices, especially under Medicare and Medicaid.
Key Takeaways
- NDC 00487-9601 (Invega Sustenna) remains a high-cost, branded therapy with stable pricing absent biosimilar competition.
- The U.S. market continues to favor LAIs for adherence benefits, maintaining steady demand.
- Price increases are modest, aligned with inflation, absent major patent expirations or regulatory disruptions.
- Future price reductions may occur if biosimilars or generics enter the market post-patent expiry.
- Reimbursement adjustments and policy reforms could influence net pricing in public payers.
FAQs
1. When is patent expiry expected for Invega Sustenna?
Patent protection is anticipated to expire around 2027, potentially opening the market to biosimilar competition.
2. How much could biosimilar entry affect prices?
Biosamilars could reduce list prices by approximately 30-50%, though uptake depends on regulatory approval, pricing strategies, and insurer negotiations.
3. What is the current reimbursement landscape?
Reimbursement rates for Invega Sustenna vary, but payer negotiations often result in net prices below list prices, especially through formularies.
4. Are there alternate formulations or generics?
No generic versions exist currently, and the formulation's complexity limits immediate generic entry.
5. How does pricing differ globally?
Globally, prices vary widely based on regulatory environments, patent status, and healthcare system structures, with some markets paying significantly less than the U.S.
Citations
[1] Market data sourced from IQVIA, 2022.
[2] Industry reports on antipsychotic markets, 2022.
[3] Public patent filings and expiry estimates, 2022.
[4] Price and reimbursement data from FDA, CMS, and leading pharmacies, 2023.
[5] Regulatory pathways for biosimilars, FDA guidance, 2022.
